Townsend Letter for Doctors and Patients
Alternative Medicine Conference Calendar
Who are we?New articlesFeatured topicsArticles onlineSubscriptionsContact us!
Check out recent tables of contents
From the Townsend Letter for Doctors & Patients
February/March 2003
The Medical Journalist Report of Innovative Biologics: Cancer Remission Rates Increase from Use of the Safe and Effective Lipoic Acid Palladium Complex Poly-MVA
by Morton Walker, DPM
Our February /March 2003 cover
Order back issues
Advertise with TLDP!
Order this issue!
Search our site

"I had this terrible bone pain in my head, spine, ribs, and all over. Then the doctor told me he had discovered holes in my skull the size of nickels and dimes. I felt just terrible pain and needed to sleep all the time to escape it. I took pain pills and sleeping pills. It turned out – the final diagnosis offered by my newly acquired oncologist – that I had been struck by multiple myeloma," states 67-year-old clergyman Kenneth Walker of Fox Island, Washington. "On March 19, 2001 he told me the diagnosis and in June he advised that because my anemia was so severe, 'The cancer is ravaging your bone marrow – you have less than three months to live unless you undergo chemotherapy.'"

Also referred to as malignant plasmacytoma or plasma cell myeloma or myelomatosis, multiple myeloma is a disseminated neoplasm of marrow plasma cells. The disease infiltrates bone to produce osteolytic lesions throughout the skeleton (particularly in the flat bones, vertebrae, skull, pelvis, and ribs). Standard treatment is cytotoxic chemotherapy using cyclophosphamid or melphalan – both administered with prednisone to suppress plasma cell growth and control pain. The medical profession considers this disease incurable. According to a respected reference source, within three months of diagnosis 52% of patients die; within two years, 90% die.1

"Today, this same oncologist advises me that if I was visiting him for the first time, he would not suspect cancer had ever been present. The treatment I researched and adopted on my own saved me," affirms Reverend Walker. "At the doctor's request I have documented what he describes as 'such a fantastic result.'"

Illustrative of the "fantastic result" for Ken Walker is that no symptoms of multiple myeloma remain. He is now retired and enjoying a leisure life to the fullest. During the late summer of 2001, for example, the retired clergyman and his wife spent six weeks circumnavigating Canada's Vancouver Island in their sailboat. During the week just prior to Thanksgiving 2002, he flew to Aruba to engage in scuba diving with dive master and Oriental medicine specialist Carlos Viana, OMD, who practices holistic medicine in Aruba and throughout the Netherlands Antilles.

Reverend Ken Walker (no relation to the author) is utilizing the newest concept in nutritional supplements, an organic "metallovitamin" and amino acid produced under three patents first issued by the US Government in October 1995 to electro-biochemist and former US Navy dentist Merrill Garnett, PhD, DDS, of Islip, Long Island, New York. This metallovitamin derived from a lipoic acid and palladium complex, will be described in detail.

Breast Cancer Remission for Sarah J. Jones

"During February 2002, I discovered a lump in my left breast that seemed pretty big," says Sarah J. Jones of Denver, Colorado. "Because I could not get an evaluation appointment at the Sally Jobe Diagnostic Center in Greenwood Village, Colorado for several weeks, I researched the holistic medical literature on my own and took a number of nutritional supplements," Sarah says. "When finally I was seen at the Sally Jobe Center, their multiple Doppler ultrasound films confirmed my breast lump as potentially cancerous. The radiologist browbeat me to have a biopsy, which I refused because of what I had learned from my reading about the spread of cancer from biopsies.

"With hands on hips and challenge in her voice, the head nurse at Sally Jobe Center announced to me, 'From their star shape, I guarantee that the cells in your breast lump are cancerous.' "If that be true," I wondered, "why do I need a biopsy?"

Sarah is married to cancer researcher Bob Jones, inventor of the Cavitat®, a sonogram diagnostic device for detecting neuralgia-inducing cavitational osteonecrosis (NICO) arising from implanted root canal teeth. The Cavitat® is renowned for its diagnostic endodontic excellence among holistic, biological, mercury-free dentists such as those who are members of the International Academy of Oral Medicine and Toxicology, the Environmental Dental Association, the American Academy of Biological Dentistry, and the Holistic Dental Association. The enlightened dentists who are members of these professional organizations consider Sarah and Bob Jones holistic dental visionaries.

"Not then or now do I receive physician-administered cancer treatment. The physician who is supervising my Doppler-ultrasound evaluations, Ob-Gyn specialist Asela C. Russell, MD, keeps insisting that I must undergo biopsy, chemotherapy, and radiation," Sarah Jones says. "The radiologist at the Sally Jobe Center's Invision Department, Virgini Stefanoudakis, MD, notes about me: 'Due to her strong beliefs in holistic medicine, she [the patient] may or may not agree to biopsy.'

"I have never undergone biopsy. Near the end of May 2002, after speaking on the phone about my breast cancer to Emmy McAllister, the director of Health Solutions Now!, Bob learned from her about the same anticancer substance containing minerals, vitamins, and amino acids used successfully by Reverend Ken Walker. Then my husband did his own literature search on the substance, Poly-MVA. Consequently, I added this liquid amino acid metallovitamin to my nutritional supplementation, two teaspoonfuls four times a day taken in purified water," confirms Sarah. "I've continued this supplementation on my own without help from any oncologist, except that Sally Jobe Center Ob-Gyn Associate Asela C. Russell, MD, monitors the size of my tumor."

Sarah Jones concludes, "After she performed an examination of me on November 8, 2002, Dr. Russell wrote on her prescription pad: 'Sarah Jones' left breast mass is significantly smaller. [Now reduced to] approximately 1.5 by 1.4 centimeters [2.1 cm3] maximum dimensions.'"

Within six months of beginning her program of nutritional supplementation with Poly-MVA, this most recent oncological measurement for the patient's cancerous breast lump shows a reduction from her original March 15, 2002 tumor measurement of 5.382 cm3. The malignant breast tumor of Sarah Jones had shrunk by 67 percent.

Both Sarah and Ken Walker are experiencing dramatic results from their use of the inventor's Poly-MVA anticancer concept. The Poly-MVA name comes from the combined terms Poly meaning "many, much, more than one"; M indicating "minerals"; V signifying "vitamins"; and A symbolizing "amino acids."2

The PolyMVA Anticancer Concept

A new principle in the nutritional healing of most cancer types is being presented here in the form of Poly-MVA™, the enzymatic complex of polynucleotide reductase which assists in correcting malfunctional nucleic acids in the deoxyribonucleic acid (DNA) of genes.3

To explain: the nucleotide component is a single building block or step up the "spiral staircase" of DNA. Nucleotides show up as vital units in DNA because they are the basic molecular structures that control cell division and replication. The reductase enzyme catalyzes oxidation/reduction by which any substance gains one or more electrons; and this enzyme invariably assists in bringing about DNA repair. Subsequently, the polynucleotide reductase that is part of the Poly-MVA molecule biochemically affects multiple units of DNA by functioning as a gene-restoring nutrient.4

As stated, the Poly-MVA molecule is a lipoic acid palladium (LAPd) complex, which accomplishes such therapeutic restoration in several ways:

1) Its vitamin complex portion improves synergy with other essential nutrients inside the errant gene.

2) Its metallic components activate cyanocobalamin (vitamin B12).

3) Its alpha lipoic amino acid component aids in energy transfer within cells, which characteristically is highly specific for transferring electron energy from a normal metabolic hydrogen carrier to nucleic acids.

Poly-MVA's inventor, Merrill Garnett, DDS, PhD, emphasizes that he chose to bind palladium (Pd) to alpha lipoic acid (ALA) because this amino acid is both water and fat-soluble and able to travel everywhere in the human body, even through the blood-brain barrier, taking the palladium molecule with it.

Dr. Garnett, whose Garnett McKeen Laboratory is located in Islip, New York, has produced a self-published book, First Pulse: A Personal Journey in Cancer Research. In it, the author-scientist offers a philosophical, highly technical but interesting anecdotal-filled discussion of how he came to create his invention. Dr. Garnett searched for singular substances for binding together the various ingredients which make up Poly-MVA. He found the therapeutic component in the platinum-derived palladium mineral, poisonous in the hands of an allopathic dentist, but life-saving for someone suffering from cancer. Yet Pd would be poisonous to cancer patients too, if it were not bound tightly to alpha lipoic acid and "sequestered" in the molecule as cobalt is sequestered in vitamin B12. Thus, Pd forms an organic metallovitamin-lipoic acid complex that joins with cobalt (Co), a part of the vitamin B12 (cyanocobalamin) complex.5

Dr. Garnett created Poly-MVA based on knowledge unknown before he discovered the Second Genetic Code, a huge scientific breakthrough and probably the crowning achievement of his career. (See the Garnett book for details about the highly complicated Second Genetic Code discovery.)

Dr. Garnett discovered that palladium acts as an excellent catalyst for combining oxygen (O) and hydrogen (H); the metal absorbs over 900 times its volume of hydrogen. He adapts Pd for strengthening the actions of other molecules too; e.g., iron (Fe) holds together the active parts of hemoglobin, and its holding action is reinforced in the presence of palladium. Other amino acids besides alpha lipoic acid make up some part of the Garnett formulation.

Poly-MVA Eliminates Brain Cancer for Mark Olsztyn

Now 38 years old, Mark Olsztyn, the son of Stanley R. Olsztyn, MD(H), popular holistic and homeopathic physician of Phoenix, Arizona, was diagnosed in 1993 with a Stage IV frontal lobe brain tumor the size of a walnut. After excision it was judged to be a low-grade pilocynic astrocytoma. Recommended follow-up was merely with periodic diagnostic Magnetic Resonance Imaging. The imaging was done for five years until Mark decided he was in wonderful shape with no more need for diagnostics.

"While working in Boston, Mark eventually visited his local physician for a routine checkup and a second tumor was found to have grown in the same location of his brain. Surgery turned up that my son now was affected by glioblastoma multiforme, a much more serious condition than the first," explains Dr. Olsztyn. "The tumor showed as unencapsulated, highly malignant, growing rapidly, and infiltrating extensively. In Boston, he took a full course of radiation therapy and then started on chemotherapy. Realizing that he was not going to live very long, Mark decided to return home to Phoenix expecting to die with his loved ones around him.

"When he came back to Phoenix in early 1998 I became an active participant in his care," states Dr. Olsztyn. "I put him on a nutritional program, carried on discussions with oncologists about chemotherapy, and acquired Poly-MVA for Mark's daily use. I invited both Dr. Merrill Garnett and Dr. Albert Sanchez, Sr., to lecture about it at our monthly Arizona Homeopathic Medical Association meeting.

"While simultaneously taking Poly-MVA and chemotherapy, my son decided to discontinue the chemotherapy altogether because of severe side effects he was experiencing. He therefore uses only his regular large daily doses of Poly-MVA," Dr. Olsztyn says. "From mid-1998, the only contact Mark has had with conventional oncological medicine is for diagnostic MRIs. Poly-MVA is the only treatment he has taken, and for nearly five years there remains no visible evidence of tumor regrowth. My son is asymptomatic and semi-annual MRI examinations are negative for brain cancer.

"I have recommended Poly-MVA to many people because of my extremely favorable impression of the Garnett concept from several viewpoints: First, the theoretical explanation of how it works makes sense," states Dr. Olsztyn. "Second, the product is completely safe and definitely effective for healthy tissue. Third, it is highly selective for malignant tissue, by influencing oxygen, water, and electrical inputs to the malignancy.

"Patients I've observed taking Poly-MVA have thrived. Numbers of them are following its protocol now. In my opinion Dr. Garnett and Dr. Sanchez are providing a really well thought out, safe treatment for all types of malignancies. They should be commended," affirms Dr. Stanley R. Olsztyn.

The Poly-MVA Mechanism of Action

As reported in An Alternative Medicine Definitive Guide to Cancer, "A major factor in the success of Poly-MVA has been to provide an electron energy transfer mechanism from normal metabolic hydrogen carriers to nucleic acids. Poly-MVA induces energy-dependent changes in the shape of DNA or RNA [ribonucleic acid] as a result of the new reduced state it induces in the nucleotides."6

Dr. Garnett's newly conceived molecule of lipoic acid palladium (LAPd) complex repairs the abnormally altered gene that sets potential cancer mechanisms in motion by following the recommended protocol for PolyMVA. The now deceased oncology therapist Rudy Falk, MD, of Barrie, Ontario, Canada, had repeatedly stated, "The greatest use of Poly-MVA is as a cancer prophylactic."

Dr. Falk experimented with Poly-MVA for several years at the University of Toronto; he was one of the first physicians worldwide to investigate the new anticancer remedy. After years of research he firmly believed that ingesting 1/2 tsp. daily of Poly-MVA would prevent cancer. Today there is an important ongoing Practioners' Study of Poly-MVA to see if Dr. Falk was correct; that it's a preventative. The volunteer practitioners and their families are participating in this 20-year study to see if they can beat the odds against cancer, because as high as malignancy statistics are among the general population, they are even more elevated among health practitioners.

A general surgeon from the Dominican Republic, Ahmad Nasri, MD, took over the late Dr. Falk's Barrie, Ontario practice nearly two years ago. Continuing to utilize Poly-MVA onward from 1997 in his own country, Dr. Nasri advises: "Going back almost fifteen years, Dr. Falk had combined the Palladium Lipoic Complex with hyaluronic acid as a targeting agent and applied them together for their anticancer effects, both intravenously and orally. [Hyaluronic acid is a glycosaminoglycan found in lubricating proteoglycans of human synovial fluid, vitreous humor, cartilage, blood vessels, skin, and the umbilical cord.]

"Dr. Falk and I also had added low dose chemotherapy, high dose vitamins, H2O2, other minerals, and vaccines to Dr. Garnett's organic mineral complex. Poly-MVA was one of our most important cancer remission tools," continues Dr. Nasri. "With Dr. Falk working in Canada and me in the Dominican Republic, we achieved excellent results against most cancers. We observed tumor shrinkage, cancer down staging from Stage 4 to Stage 2, pain reduction, and additional therapeutic effects. Cancer patients we had started on this protocol even eight years ago remain in good health by self-administration of the oral liquid and periodically receiving intravenous booster injections of Poly-MVA. My practice today involves following the patients' progress with tumor markers, and resuming their IV treatment if necessary. Today I can definitely offer at least six cancer case histories of patients who stay in good shape from their taking Poly-MVA."

Poly-MVA is manufactured as a liquid mostly for oral ingestion, although some physicians administer it intravenously (see the procedure reported below by David C. Korn, MD(H), DO, DDS, of Apache Junction, Arizona).

Dr. Falk's original anticancer usage protocol strictly for cancer prevention consisted of only 1/2 teaspoonful a day of Poly-MVA. For therapy, a new and updated Poly-MVA protocol is now enthusiastically recommended by the Advanced Medicine and Research Center (AMARC) of Chula Vista, California. The protocol is presented in a publication written by Albert Sanchez, Sr., PhD, EdS, and made available by AMARC.7

Poly-MVA Administered Intravenously

"Since PC Spes was removed from the market by the FDA almost two years ago, I have substituted the administration of both intravenous and oral Poly-MVA for prostate cancer patients and found it to act effectively. After receiving the new product IV for six or eight weekly injections and simultaneously taking the liquid in water, my male patients find their prostate specific antigen (PSA) markers come down. They go on to take the oral liquid Poly-MVA alone for approximately ten or twelve weeks more. This protocol affords great results. Recently two of my patients dropped down to a PSA of one (1) from much higher markers," states David C. Korn, DO, DDS, MD(H), of Apache Junction, Arizona.

"I believe that saturating the blood with Poly-MVA insures the nutrient's elevated dosage swiftly penetrates into the prostate area, the brain, and other organ sites. The patient with blood saturation of Poly-MVA goes through a physiologic range of reactions illustrated by an elevation of body temperature," warns Dr. Korn. "I administer the treatment for lymphoma, brain cancer, breast cancer, prostate cancer, and more.

"Insulin potentiation therapy works well in conjunction with Poly-MVA. But for elderly men with bone pain from prostate metastases who are frail, my preference is to administer the Garnett treatment alone. It acts just like a 'smart bomb' for pain relief, requiring four or five hours of the IV Poly-MVA. Based on an educated estimate of tolerated IV liquid, my staff and I gradually increase the dosage to 15 or 20 cc," advises Dr. Korn. "I additionally include vitamin E, CoEnzyme Q10, lycopene, saw palmetto, and other prostate-specific nutrients.

"My impression is that the Poly-MVA molecule actually behaves like a mild chemotherapeutic agent, but it is safe and not destructive. Moreover, the Lipoic Acid Palladium Complex is highly effective for increasing cancer remission rates," confirms David C. Korn, DO, DDS, MD(H).

Recognized Poly-MVA Therapeutic Benefits

From the established therapeutic effects of its alpha lipoic acid/palladium complex, Poly-MVA provides at least 13 recognized anticancer benefits. The benefits are reproduced here from observations described by Dr. Merrill Garnett in a series of reports published on his animal studies conducted at the Garnett McKeen Laboratory in Islip, New York. One by one over time, he has advised that the lipoic acid/palladium complex (LAPd) does the following:8

1. LAPd causes an indefinite variety of immune system responses, but with specific manifestations as indicated in the twelve additional attributes listed below.

2. LAPd seeks out and destroys cancer cells anywhere in the body by stealing their electromagnetic energy.

3. LAPd invigorates normal cells and helps to repair any damage the invasive cancer may have left behind.

4. LAPd reduces tumor size or causes the tumor to shink.

5. LAPd produces an idiosyncratic set of effects which include a pattern of lag-arrest-slow death of cancer cells from an inhibition of their energy metabolism.

6. LAPd prevents sterol biosynthesis, thereby preventing new cancer cell plasma membrane synthesis.

7. LAPd shows a very large fraction of sensitive cancer cells as a morphological feature.

8. LAPd promotes the growth of proliferating normal cells surrounding a core of central tumor necrosis consisting of dead cancer cells.

9. LAPd stimulates the infiltration of leukocytes for the removal of cancer cell debris.

10. LAPd has absolutely no toxic reaction – no adverse side effects.

11. LAPd accomplishes its therapeutic benefits in both animals and humans.

12. LAPd works against cancer of many types not only as an orally administered liquid but also perhaps even more effectively as an intravenous injection.

 13. LAPd reduces the incidence of cachexia with a potential for increased body weight of the frail cancer patient.

Being aware of the LAPd actions in Poly-MVA, Robert D. Milne, MD, Medical Director of the Milne Medical Center in Las Vegas, Nevada, has employed the metallovitamin complex for a family member and for the adjunctive nutritional healing of cancer in numbers of patients. He does not treat cancer but offers his patients nutritional support for their cancer. Poly-MVA is one of the more vital nutrients that Dr. Milne recommends.

"After undergoing a full oncological evaluation, my father-in-law at age 69 asked me to help him with a potentially deadly 14-cm by 2.5 cm-size Stage 3 transitional cell carcinoma of the bladder producing right-ureter obstruction," explains Dr. Milne. "Hospitalized in a critical care unit for ten days with acute respiratory distress syndrome from his adverse reaction to chemotherapy, my father-in-law was no longer a candidate for cytotoxic therapy. Upon my educating him about Poly-MVA, he undertook a therapeutic trial of this nutritional agent. With the Poly-MVA, I also recommended that he take 500 mg daily of coenzyme Q10 and 25 tablets daily of pancreatic enzymes. The treatment proved successful for him.

"His original tumor biopsy taken July 2001 was reported by the pathologist as 'invasive carcinoma Grade 2 with invasion into the muscularis propria.' Using just the nutritional program I had recommended," says Dr. Milne, "a report on the six-month followup biopsy of my father-in-law's tumor on January 11, 2002 stated, 'There is no cancer.' And his CAT scan showed, 'No evidence of the tumor in this patient's bladder.'

"I believe that the Poly-MVA adjunct for this patient was exceedingly helpful, and the work of Dr. Merrill Garnett is truly remarkable. It's different from any other therapy that has ever been done against cancer," says Dr. Robert D. Milne. "Based on my father-in-law's excellent result and the results experienced by many others, I truly believe that Poly-MVA is worth trying by any person who has cancer or wants to prevent its onset."


Further information about Merrill Garnett, PhD, DDS, and his work in the field of bio-energetics may be found on Dr. Garnett's website at

People wanting additional information about Poly-MVA should visit the particular website at

Anyone requiring a contact list of cancer survivors who have benefited from Poly-MVA and for a second list of over 150 health professionals who provide patients with Poly-MVA, should visit the survivors' website at

Health professionals and others seeking information about how to participate in the Practitioners' Study on Poly-MVA, may acquire a complimentary practitioners' informational packet, which includes Dr. Garnett's published book, First Pulse, plus more general material about the LAPd molecule of Poly-MVA. Make your request to Emmy McAllister at Health Solutions Now!, P.O. Box 1177, Snohomish, Washington 98291; 425-334-9644; Fax 425-334-9834; Email:

Ms. Emmy McAllister is the information agent representing the charitable organization responsible for supporting Dr. Merrill Garnett's metallochemical research, the Advanced Medicine and Research Center (AMARC), Albert Sanchez, PhD, EdS, President, 539 Telegraph Canyon Road, #281, Chula Vista, California 91910; 619-628-4751 or 619-628-4745; Fax 619-628-4749; Email:

Health professionals having more technical biochemical/physiological questions may telephone the inventor/creator of Poly-MVA, Dr. Merrill Garnett, directly at his office in Islip, New York at 631-774-3821.

Persons wishing to acquire a supply of oral Poly-MVA and other nutritional substances may contact the primary commercial source in North America, AMARC Enterprises, Inc., Albert Sanchez, Jr., President; 866-Poly-MVA i.e. 866-765-9682; Email:

For further information about his multiple myeloma remission experience, contact Reverend Ken Walker, 221 Bella Vista Drive, Fox Island, Washington 98333; 253-549-7676; Email:

For further information about her breast cancer reduction experience, contact Sarah Jones, Cavitat Medical Tech Inc., 10691 East Bethany Drive, Suite 900, Aurora, Colorado 80014-2670; 303-755-2688.

For further information about therapy for his son Mark or other patients taking the Poly-MVA, contact Stanley R. Olsztyn, MD, 4350 East Camelback Road, Suite B-220, Phoenix, Arizona 85018; 602-840-8424; Email:

For further information about his experience administering Poly-MVA and the adaptation of Dr. Rudy Falk's original protocol, contact Ahmed Nasri, MD, 730 Essa Road, Barrie, Ontario, Canada L4N 9E9; Tel. 705-735-2354; Email:

For further information about his experience with the IV injection of Poly-MVA, contact David C. Korn, D.O., D.D.S., M.D.(H), Long Life Medical Incorporated, 11518 East Apache Trail, Suite 115, Apache Junction, Arizona 85220; 480-354-6700; Email

For his summary judgement about the anticancer qualities of Poly-MVA, contact Robert D. Milne, M.D., Medical Director of the Milne Medical Center, 2110 Pinto Lane, Las Vegas, Nevada 89106; 702-385-1393; Email:


1. Diseases, 2nd Edition. (Springhouse, Pennsylvania: Springhouse Corporation, 1997), pp. 362-364.

2. Sanchez, A. What You Must Know to Overcome Cancer. (Chula Vista, California: ARMARC, 2001), pp. 51-54.

3. Garnett McKeen Laboratories: Nucleotide reductase. U.S. Patent No. 557,637 (October 31, 1995).

4. Diamond, W.J.; Cowden, W.L.; Goldberg, B. An Alternative Medicine Definitive Guide to Cancer. (Tiburon, California: Future Medicine Publishing, Inc., 1997), p. 506.

5. Garnett, M. First Pulse: A Personal Journey in Cancer Research, Second Edition. (New York, New York: First Pulse Projects, Inc., 2001).

6. Op. cit. Diamond, Cowden, Goldberg, p. 506.

7.   Poly-MVA Cancer Breakthrough: Palladium Lipoic Complex. (Chula Vista, California: AMARC, 2001), p. 4.

8. Ibid, the entire text.



Visit our pre-2001 archives

Search our pre-2001 archives for further information. Older issues of the printed magazine are also indexed for your convenience.
1983-2001 indices
; 1999-Jan. 2003 indices
Once you find the magazines you'd like to order, please use our convenient form, e-mail, or call 360.385.6021 (PST).

© 1983-2002 Townsend Letter for Doctors & Patients
All rights reserved.
Web site by Sandy Hershelman Designs
June 13, 2003